96
Views
15
CrossRef citations to date
0
Altmetric
Original Research

Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy

, , , , , & show all
Pages 9-17 | Published online: 21 Dec 2016

Figures & data

Figure 1 Patient distribution by biologic drug at baseline.

Figure 1 Patient distribution by biologic drug at baseline.

Table 1 Baseline demographic, therapeutic and clinical characteristics of patients enrolled in the study

Figure 2 Persistence with biologic therapy: adalimumab, etanercept and infliximab.

Notes: First year: Eta vs. Ada p=0.69; Eta vs. Inf p=0.007; Ada vs. Inf p=0.32. Second year: Eta vs. Ada p<0.001; Eta vs. Inf p=0.002; Ada vs. Inf p=0.54. Third year: Eta vs. Ada p=0.008; Eta vs. Inf p=0.014; Ada vs. Inf p=0.88. Fourth year: Eta vs. Ada p=0.002; Eta vs. Inf p=0.031; Ada vs. Inf p=0.62.
Abbreviations: Eta, etanercept; Ada, adalimumab; Inf, infliximab.
Figure 2 Persistence with biologic therapy: adalimumab, etanercept and infliximab.

Figure 3 Percentage of patients switching from initial therapy.

Notes: First year: Eta vs. Ada p=0.05; Eta vs. Inf p=0.25; Ada vs. Inf p=0.55. Second year: Eta vs. Ada p=0.18; Eta vs. Inf p=0.05; Ada vs. Inf p=0.64.
Abbreviations: Eta, etanercept; Ada, adalimumab; Inf, infliximab.
Figure 3 Percentage of patients switching from initial therapy.

Figure 4 Percentage of patients with drug consumption escalation.

Abbreviations: Eta, etanercept; Ada, adalimumab; Inf, infliximab.
Figure 4 Percentage of patients with drug consumption escalation.

Figure 5 Percentage of patients with drug consumption reduction.

Abbreviations: Eta, etanercept; Ada, adalimumab; Inf, infliximab.
Figure 5 Percentage of patients with drug consumption reduction.

Table 2 Multivariable logistic regression model of persistence to therapy and switching among biologic agents

Figure 6 Costs for the three biologics investigated*.

Notes: *Excluding infusion costs for infliximab.
Figure 6 Costs for the three biologics investigated*.

Figure 7 Costs for other health care consumption (excluding drugs).

Figure 7 Costs for other health care consumption (excluding drugs).

Table 3 Mean annual costs of treatment per indicator of pharmacological consumption.

Table 4 Cost of illness, generalized linear model